(Q33835933)

29 July 2017

1 reference

title

Adjuvant chemotherapy for high-risk endometrial cancer (English)

1 reference

29 July 2017

1 reference

1 reference

Pustilnik T

1

1 reference

29 July 2017

Burke TW

series ordinal

2

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Seminars in Radiation Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

23-28

1 reference

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

A randomized trial of adjuvant progestagen in early endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Postoperative external pelvic irradiation in carcinoma of the corpus stage I: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Uterine papillary serous carcinoma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Phase II evaluation of carboplatin in advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980017-X

7 January 2021

10.1016/S1053-4296(00)80017-X

Identifiers

DOI

1 reference

29 July 2017

1 reference